TherapeuticsMD(US:TXMD)2022-03-10 15:35Financial Data and Key Metrics Changes - The company's net product revenue for Q4 2021 was $18.7 million, a decrease of 15% compared to Q4 2020 [17] - ANNOVERA's net revenue increased by 14% year-over-year to $7.8 million, despite production and supply issues [17] - IMVEXXY's net revenue decreased by 24% year-over-year to $6.7 million, primarily due to a decrease in sales volume [18] - Gross profit margin was 75% in Q4 2021, negatively impacted by approximately $700,000 from BIJUVA export sales [19] - Total operating expenses were $49.3 million, including $4.5 million in severance-related expenses [19] Business Line Data and Key Metrics Changes - ANNOVERA saw a significant increase in demand, with total prescriptions rising by 11% quarter-over-quarter and 57% year-over-year [23] - IMVEXXY and BIJUVA experienced flat to slightly down total prescriptions, indicating a shift in focus towards ANNOVERA [25] Market Data and Key Metrics Changes - The company is experiencing strong demand for ANNOVERA, with significant unfilled orders at the end of Q4 2021 [17] - The market awareness for ANNOVERA among healthcare providers increased to 87% from 67% [33] Company Strategy and Development Direction - The company aims to transform into a focused women's healthcare company, emphasizing the empowerment of women through better healthcare [8] - A new capitalization plan has been initiated, including the divestiture of vitaCare for $150 million, which will help reduce annual costs by $60 million [11][15] - The company is committed to achieving EBITDA breakeven by Q4 2022 [7] Management's Comments on Operating Environment and Future Outlook - Management acknowledges supply challenges for ANNOVERA but believes these are temporary and will be resolved by the end of Q1 2022 [8] - The leadership team is focused on accountability and delivering on immediate priorities without overpromising [40] - The company anticipates providing earnings guidance in Q2 2022, once there is more visibility on supply and financial forecasts [14][42] Other Important Information - The company has amended its credit agreement with Sixth Street to provide financial flexibility, including waiving certain covenants [16] - The company has implemented changes to improve manufacturing processes and reduce batch rejections, aiming for increased production capacity [46][48] Q&A Session Questions and Answers Question: How will the new management team do things differently than the prior one? - The management team is focused on accountability and delivering on immediate priorities, looking forward rather than backward [39] Question: What would ANNOVERA sales have been in Q4 2021? - There was an estimated 6,000 rings that could have been delivered, indicating a better performance if supply issues had not occurred [41] Question: Can you provide more details on the Sixth Street loan and cash position after June? - The proceeds from the vitaCare divestiture will be used to refinance the Sixth Street debt, ensuring sufficient cash for the foreseeable future [42] Question: What is the confidence level regarding ANNOVERA manufacturing issues? - The company believes it can meet demand starting around Q2 2022, even without FDA approval of the manufacturing supplement [45] Question: How is the company balancing the commitment to EBITDA profitability with growth? - The company is undergoing a reset of its commercial approach while maintaining a focus on achieving EBITDA profitability [49]